Wall Street Zen Downgrades Grifols (NASDAQ:GRFS) to Hold

Key Points

• Wall Street Zen downgraded Grifols (NASDAQ:GRFS) from a "buy" to a "hold," while Weiss Ratings cut it to a "sell;" MarketBeat shows a consensus rating of "Reduce" and an average target price of $10.00.
• Shares opened at $8.23 with a market cap of $5.6 billion, a P/E of 43.32 and a 52-week range of $7.08–$11.14; last quarter the company reported $0.38 EPS on $2.32 billion in revenue and a 5.34% net margin.
• Despite downgrades, several institutional investors (e.g., Versant Capital, Mirae Asset, Peterson Wealth Services) have modestly increased their holdings, signaling some continued buying interest.

Grifols (NASDAQ:GRFS - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a note issued to investors on Saturday.

Several other analysts also recently commented on GRFS. Weiss Ratings downgraded shares of Grifols from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. Zacks Research upgraded shares of Grifols from a "strong sell" rating to a "hold" rating in a report on Friday, February 6th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Reduce" and an average target price of $10.00.

Grifols Stock Performance

Shares of NASDAQ:GRFS opened at $8.23 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.51 and a quick ratio of 0.88. The company has a market capitalization of $5.60 billion, a price-to-earnings ratio of 43.32, a P/E/G ratio of 0.26 and a beta of 0.70. The firm's 50 day simple moving average is $8.29 and its 200 day simple moving average is $8.82. Grifols has a fifty-two week low of $7.08 and a fifty-two week high of $11.14.

Grifols (NASDAQ:GRFS - Get Free Report) last announced its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. The firm had revenue of $2.32 billion for the quarter. Grifols had a net margin of 5.34% and a return on equity of 6.23%. As a group, sell-side analysts forecast that Grifols will post 1.18 earnings per share for the current year.

Institutional Trading of Grifols

Several hedge funds have recently bought and sold shares of the stock. Versant Capital Management Inc raised its holdings in shares of Grifols by 39.5% in the third quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 1,584 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Grifols by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 1,212 shares during the last quarter. Peterson Wealth Services raised its holdings in shares of Grifols by 385.8% in the third quarter. Peterson Wealth Services now owns 7,287 shares of the biotechnology company's stock valued at $73,000 after purchasing an additional 5,787 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Grifols by 15.7% in the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company's stock valued at $75,000 after purchasing an additional 1,096 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Grifols by 127.4% in the second quarter. EverSource Wealth Advisors LLC now owns 8,219 shares of the biotechnology company's stock valued at $74,000 after purchasing an additional 4,604 shares during the last quarter.

Grifols Company Profile

Grifols, Inc NASDAQ: GRFS is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.